Meetings & Events

Challenges in Diagnosing and Managing Patients with Fibrodysplasia Ossificans Progressiva

August 16, 2021

Session Date and Time:

Friday, September 10
3:10–4:40 PM EDT

Learning Objectives:

  1. Analyze clinical presentations of FOP in individuals.
  2. Review the importance of early diagnosis and management of FOP.
  3. Describe the best practices in the diagnosis and management of patients with FOP.


3:10–3:15 PM EDT Welcome and Introduction
Kelly L. Wentworth, MD
3:15–3:50 PM EDT Clinical Presentation and Treatment Options for Patients with FOP
Mona Al Mukaddam, MD, MD
Elisabeth M. W. Eekhoff, MD, PhD
3:50–4:05 PM EDT
Basic and Translational Science Advancements in FOP
Benjamin Levi, MD
4:05–4:20 PM EDT  Future Management Options for Patients with FOP
Elisabeth M. W. Eekhoff, MD, PhD
4:20–4:40 PM EDT
Post-test, Panel Discussion, and Q&A


This session is certified for 1.5 AMA PRA Category 1 Credits™ and ABIM MOC Points.

Please note, there is no cost to participate, and registration is open to anyone with Endocrine Society login credentials, not exclusive to our members or registrants of CEU or EBR 2021. However, there is limited space and registration is encouraged. Register for this session today.

Register Now

Return to the full CEU 2021 program.

This program is supported by an educational grant from Ipsen Biopharmaceuticals, Inc.

Faculty Information

Kelly L. Wentworth, MD

Kelly Wentworth, MD, is an Assistant Professor in the Department of Medicine, Division of Endocrinology at Zuckerberg San Francisco General Hospital, University of California, San Francisco. She has a clinical and research interest in metabolic bone disorders, with a specific focus on fibrous dysplasia/McCune-Albright Syndrome and fibrodysplasia ossificans progressiva (FOP). She is currently funded by an NIH/NIDCR K08 career development grant. 

Mona Al Mukaddam, MD, MSMona Al Mukaddam, MD, MS, is an adult endocrinologist in the Division of Endocrinology, Diabetes and Metabolism at the Pennsylvania and Director of the Penn Bone Center. Dr. Al Mukaddam received her Bachelor of Science and Medical Degrees from American University in Beirut, Lebanon. She completed her internship and residency in internal medicine at the University of Iowa, a fellowship in the Division of Endocrinology, Diabetes and Metabolism at Penn, and received a Master of Science Degree in translational medicine and therapeutics at the University of Pennsylvania.

Dr. Al Mukaddam is board certified in endocrinology, diabetes and metabolism. She is the principal investigator on ongoing clinical trials in FOP at the Center for Research in FOP & Related Disorders at Penn and is a founding member of the International Clinical Council on FOP (ICC).

Elisabeth M. W. Eekhoff, MD, PhDMarelise Eekhoff, MD, PhD, is an internist-endocrinologist, working as a staff member at the Department of Internal Medicine, Department of Endocrinology of the University Medical Centers Amsterdam, location VU (VUmc), Amsterdam, the Netherlands since 2002.

She completed her internal medical education at the Leiden University Medical Center (LUMC), Leiden, the Netherlands. She then worked for more than a year in the Intensive Care Unit, followed by her endocrinology studies at the Endocrinology Department of the LUMC in Leiden. In the same period, she conducted her thesis "Paget's bone disease in the Netherlands: epidemiology, genetics and treatment" (PhD 2004).

Since 2002, she has worked as an internist-endocrinologist with a focus on rare bones and endocrine disorders, including outpatient clinical care, education and research. Her expertise is rare bone diseases, in particular fibrodysplasia ossificans progressiva (FOP) since 2012. Marelise and her team at the Amsterdam UMC - VU, have been officially awarded as a national center of expertise in FOP (in addition to expertise in osteogenesis imperfecta (OI), fibrous dysplasia (FD, skull) and X-linked / genetic osteoporosis; all part of the Amsterdam Bone Center (ABC)).

Marelise and her team are focusing their research on an integrated approach with patients, other researchers and companies to find new diagnostic tools and new treatment methods for FOP (/ rare bone diseases), with treatment for prevention and recovery as the main goal.


Benjamin Levi, MDBenjamin Levi, MD, holds the Dr. Lee Hudson-Robert R. Penn Chair in Surgery and Plastic and Reconstructive Surgery and serves as Chief of the Division of Burn, Trauma, Acute and Critical Care Surgery. He specializes in acute and reconstructive burn surgery and scar reconstructive surgery.

Certified by the American Board of Plastic Surgery and the American Board of Surgery, Dr. Levi joined the UT Southwestern faculty in 2020. Previously, he was Director of the Burn/Wound and Regenerative Medicine Laboratory and Associate Director of Burn Surgery Service at the University of Michigan.

Dr. Levi’s research interests, which are funded by the National Institutes of Health, the American College of Surgeons, and the Department of Defense, include stem cell biology, heterotopic ossification, muscle fibrosis, tissue regeneration, wound healing and repair, and burn reconstruction outcomes.

He is the author of more than 100 scholarly articles, including high-impact papers in Science Translational Medicine, Proceedings of the National Academy of Sciences, and Nature Communications, as well as chapters in a number of textbooks, including Greenfield’s Surgery, Total Burn Care, Grabb and Smith’s Plastic Surgery, and Trauma. He has delivered presentations worldwide, held numerous invited professorships, and serves as a permanent editor and ad hoc editor for journals in his area of research.



Last Updated:
Back to top

Who We Are

For 100 years, the Endocrine Society has been at the forefront of hormone science and public health. Read about our history and how we continue to serve the endocrine community.